AYTU (STOCKS)
AYTU BioPharma, Inc. Common Stock
$2.590000
+0.040000 (+1.57%)
Prev close: $2.550000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Joshua R. Disbrow
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $27.69M
- Employees
- 83
- P/E (TTM)
- -0.67
- P/B (TTM)
- 1.93
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q2)
|
$-1.05 | $-0.61 | -0.4380 | -71.57% |
|
Sep 2025 (Q1)
|
$0.21 | $-0.23 | +0.4446 | +189.51% |
|
Jun 2025 (Q4)
|
$-2.92 | $-0.04 | -2.8826 | -7,707.49% |
|
Mar 2025 (Q3)
|
$0.21 | $-0.17 | +0.3834 | +221.11% |
Financial Statements
| Revenues | $62.64M |
| Benefits Costs and Expenses | $86.88M |
| Cost Of Revenue | $20.77M |
| Costs And Expenses | $86.88M |
| Gross Profit | $41.87M |
| Operating Expenses | $50.55M |
| Research and Development | $378.00K |
| Operating Income/Loss | -$8.68M |
| Income/Loss From Continuing Operations After Tax | -$24.56M |
| Income/Loss From Continuing Operations Before Tax | -$24.24M |
| Income/Loss From Discontinued Operations Net Of Tax | $116.00K |
| Income Tax Expense/Benefit | $315.00K |
| Net Income/Loss | -$24.44M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$24.44M |
| Net Income/Loss Available To Common Stockholders, Basic | -$24.44M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.42 |
| Basic Average Shares | 16,041,544 |
| Assets | $122.00M |
| Current Assets | $76.24M |
| Inventory | $8.66M |
| Other Current Assets | $67.59M |
| Noncurrent Assets | $45.76M |
| Fixed Assets | $484.00K |
| Intangible Assets | $43.58M |
| Other Non-current Assets | $1.70M |
| Liabilities | $107.80M |
| Current Liabilities | $65.56M |
| Accounts Payable | $14.26M |
| Wages | $2.29M |
| Other Current Liabilities | $49.01M |
| Noncurrent Liabilities | $42.24M |
| Equity | $14.20M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $14.20M |
| Liabilities And Equity | $122.00M |
| Net Cash Flow From Operating Activities | -$595.00K |
| Net Cash Flow From Operating Activities, Continuing | -$595.00K |
| Net Cash Flow From Investing Activities | -$3.10M |
| Net Cash Flow From Investing Activities, Continuing | -$3.10M |
| Net Cash Flow From Financing Activities | $13.33M |
| Net Cash Flow From Financing Activities, Continuing | $13.33M |
| Net Cash Flow | $9.63M |
| Net Cash Flow, Continuing | $9.63M |
| Comprehensive Income/Loss | -$24.44M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$24.44M |
| Other Comprehensive Income/Loss | $0.00 |